Welcome
We manage the Government's investment in health research. Our vision is to improve the health and quality of life of all New Zealanders.
Funding Opportunities
The HRC allocates funding through an annual funding round for researcher initiated projects, Requests for Proposals, and a range of career development awards.
About Us
We invest in a broad range of research on issues important to New Zealand, and support the development of health research careers. Our mission is 'benefiting New Zealand through health research'.
News and Publications
We produce a wide range of publications and documents, which provide information about funding opportunities, research outcomes and HRC-related news.
Ethics and Regulatory
We help ensure all research involving human participants is based on good science, meets ethical standards and complies with best practice.
Contact Us
If you have any questions about the HRC or would like to know more about how our funding process works, please drop us a line.
Gene Technology Advisory Committee
Associate Professor Greg Anderson
2016 Funding Round - Project
Associate Professor
Greg
Anderson
University of Otago, Dunedin
Targeting the RFRP neuronal system to control stress and anxiety
$1,189,211
36 months
Lay summary
| Hyperactivity of the stress axis is thought to be one of the fundamental underlying drivers of psychiatric conditions such as generalised anxiety and depression. This has led us and others to develop pharmacological approaches to modify neural stress pathways in the brain. Along these lines, we have recently discovered that the neuropeptide RFRP-3 induces anxious behaviour and enhances acute stress responses in mice. Remarkably, blockade of its receptor with a novel antagonist called GJ14 overcomes these responses. Using powerful new transgenic mouse lines and single cellular through to in vivo behavioural measurements, we will evaluate the role of RFRP-3 on activity of the cells controlling the stress axis, stress hormone secretion and various anxiety-related behaviours. We will then develop and evaluate new RFRP-3 receptor antagonists with improved ability to enter the brain following oral delivery, potentially opening an entirely new avenue for treating stress and anxiety related disorders. |
Print